Recombinant Human Cysteinyl leukotriene receptor 2 (CYSLTR2), partial

1. Its mutation is found in patients with meningeal melanocytic tumour. PMID:29476293
2. our study identifies CYSLTR2 L129Q alterations as a previously unrecognized activating mutation in blue nevi, occuring in a mutually exclusive fashion with known GNAQ and GNA11 mutations. PMID:27934878
3. The expression of CysLTR1 and CysLTR2 is higher in the lymphocytes of hyperplasic tonsils in nonallergic children PMID:27221082
4. findings implicate CYSLTR2 as a uveal melanoma oncogene and highlight the critical role of Galphaq signaling in uveal melanoma pathogenesis PMID:27089179
5. CysLTRs -1 and -2 seem to be involved in lymphocyte maturation that occurs in tonsils, without influence of allergies. PMID:27115897
6. CysLT2 receptors were expressed in lung specimens isolated from asthma subjects. Activation of CysLT2 receptors may contribute to antigen-induced bronchoconstriction in certain asthma population. PMID:26433531
7. Autocrine activity of cysteinyl leukotrienes in human vascular endothelial cells: Signaling through the CysLT receptor PMID:25839425
8. CysLTR-1 and CysLTR-2 are highly expressed in the adenoid tissues from children with AH, suggesting that leukotrienes are involved in the pathogenesis of AH. PMID:25760841
9. Suggest that endothelial and nonendothelial CysLT2R niches have separate roles in mediating inflammatory responses in ischemic/perfusion injury. PMID:24285579
10. ATRA treatment induces CysLT(2)R mRNA and protein expression in colon cancer cell lines PMID:23829413
11. CysLT2 receptor plays a primary role in the vascular responses in the upper respiratory tract. PMID:23524649
12. increased expression in tonsillar tissues of Chinese children with sleep-disordered breathing PMID:22634478
13. There is a protective role against tumor progression for CysLT(2)R and that it highlights new possibilities to regulate the CysLT(2)R. PMID:22194989
14. The synthesis of cys-LTs from LTA(4) by endothelial cells is directly associated with the activation of the CysLT(2) receptor in a typical autocrine fashion. PMID:21753081
15. Cysteinyl leukotriene receptor 2 gene polymorphism -1220 A/C is not associated with atopic dermatitis or psoriasis vulgaris in Japanese patients. PMID:21352274
16. upon ligand activation, CysLT(1)R is tyrosine-phosphorylated and released from heterodimers with CysLT(2)R and, subsequently, internalizes from the plasma membrane to the nuclear membrane in a clathrin-, arrestin-3-, and Rab-5-dependent manner PMID:21203429
17. results indicate that the M201V polymorphism drastically affects CysLT(2) responses to LTD(4) and less to LTC(4) PMID:20966037
18. Data show functional expression of CysLT1 and 2 receptors on human platelets and demonstrate that CysLTs induced the release of significant amounts of RANTES, which suggests a novel role for human platelets in CysLT-mediated allergic inflammation. PMID:20433311
19. Ca2+ fluxes elicited by CysLT in these vascular endothelial cells emanate from perturbation of the CysLT2R, rather than the expected CysLT1R. PMID:12816881
20. mast cells express the type 2 receptor for cysLTs (CysLT2R) as well, and that the amount of surface CysLT2R protein increases in response to priming with IL-4 PMID:13679572
21. Mutations in cysteinyl leukotriene 2 receptor is associated with atopy PMID:14515063
22. identified three novel exons in the 5' untranslated region of CYSLTR2 and eight novel polymorphisms; the -1220A > C polymorphism is associated with the development of asthma PMID:15454733
23. 601A>G coding polymorphism in the CYSLT2 receptor alters the potency of LTD4 PMID:15475736
24. Endothelial CysLT2R increases vascular permeability & recruits neutrophils via enhanced P-selectin expression. It may participate in hypotensive anaphylaxis. CysLT2R-dependent NO formation interacts with superoxide to form peroxynitrite. PMID:15545522
25. CysLT 1 expression predominates on inflammatory leukocytes in aspirin-sensitive rhinosinusitis. Effects of cysteinyl leukotrienes on glands and epithelium may be mediated predominantly through cysLT 2. Potentially important therapeutic implications. PMID:15696087
26. Because LTD4 and thrombin are likely to be formed concomitantly in vivo, cysLT2-R and PAR-1 may cooperate to augment vascular injury. PMID:16606835
27. CYSLTR2 and ALOX5 polymorphisms may predispose a minority of individuals to excessive cysteinyl-leukotriene concentrations, yielding a distinct asthma phenotype most likely to respond to leukotriene modifier pharmacotherapy. PMID:17460547
28. CysLT1R and CysLT2R expression in monocytes can be regulated by CysLT itself and T(H)2 cytokines at the transcriptional level. PMID:17941281
29. Since prostacyclin is a major blood vessel-protective and anti-thrombotic eicosanoid, the EC cysLT(2)-R may limit its otherwise pro-inflammatory actions through a protective Ca(2+)/calcineurin/NFAT-dependent COX-2 feedback loop PMID:17991613
30. the potential implication of CysLT2 in the inflammatory response through the modulation of chemokine gene transcription. PMID:18048362
31. Our results reveal that CysLT(2)R can mediate inflammatory reactions in a vascular bed-specific manner by altering transendothelial vesicle transport-based vascular permeability. PMID:18779380
32. increase in urinary levels is associated with anaphylaxies and eosinophilic pneumonia PMID:18946233
33. The sequence variants of CysLTR2 may affect its transcription and the stability of its mRNA, resulting in altered expression of CysLTR2 protein, which in turn causes some asthmatics to be susceptible to aspirin hypersensitivity PMID:19840403

Show More

Hide All

HGNC: 18274

UNIGENE: Hs.253706

KEGG: hsa:57105

STRING: 9606.ENSP00000282018

OMIM: 605666